Redefining KRAS treatment
We are developing next-generation KRAS-targeted therapies designed to overcome the limitations of existing treatment approaches and expand therapeutic opportunities across multiple cancers and treatment settings.
We are a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers. Combining deep expertise in biology, chemistry and computational drug design, we are advancing a pipeline of KRAS-targeted therapies with the potential to address significant unmet needs across multiple cancers, including colorectal and pancreatic cancers.
Our lead product candidate, ALTA3263, is a KRAS-selective, pan-mutant (ON/OFF) inhibitor designed to target a broad range of KRAS mutations.
We are developing next-generation KRAS-targeted therapies designed to overcome the limitations of existing treatment approaches and expand therapeutic opportunities across multiple cancers and treatment settings.
We are continuing to advance ALTA3263 in a Phase 1/1b clinical trial in KRAS-mutant advanced solid tumors.
Our mission-driven team has a proven track record of delivering small molecule oncology drugs to patients in need.
If you share our vision to transform the lives of people with cancer, come join us.
LEARN MORE
Voted one of San Diego Business Journal’s Best Places to Work four years in a row.